2023
DOI: 10.1186/s13011-023-00564-9
|View full text |Cite
|
Sign up to set email alerts
|

The impact of relaxing restrictions on take-home doses during the COVID-19 pandemic on program effectiveness and client experiences in opioid agonist treatment: a mixed methods systematic review

Alison Adams,
Sarin Blawatt,
Tianna Magel
et al.

Abstract: Background The COVID-19 pandemic led to an unprecedented relaxation of restrictions on take-home doses in opioid agonist treatment (OAT). We conducted a mixed methods systematic review to explore the impact of these changes on program effectiveness and client experiences in OAT. Methods The protocol for this review was registered in PROSPERO (CRD42022352310). From Aug.–Nov. 2022, we searched Medline, Embase, CINAHL, PsycInfo, Web of Science, Cochra… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2025
2025

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 12 publications
(1 citation statement)
references
References 128 publications
0
1
0
Order By: Relevance
“…In Taiwan, methadone-based opioid agonist treatment entails daily visits to clinics for medication administration, overseen by a nurse. The advent of the COVID-19 pandemic in 2019 has compelled adjustments in methadone treatment approaches (5), such as incorporating mobile outreach (6), waiving urine toxicology screening, and authorizing take-home methadone (7)(8)(9). Adapting opioid agonist treatment to the evolving landscape during the pandemic is imperative, necessitating flexibility while upholding treatment effectiveness.…”
Section: Introductionmentioning
confidence: 99%
“…In Taiwan, methadone-based opioid agonist treatment entails daily visits to clinics for medication administration, overseen by a nurse. The advent of the COVID-19 pandemic in 2019 has compelled adjustments in methadone treatment approaches (5), such as incorporating mobile outreach (6), waiving urine toxicology screening, and authorizing take-home methadone (7)(8)(9). Adapting opioid agonist treatment to the evolving landscape during the pandemic is imperative, necessitating flexibility while upholding treatment effectiveness.…”
Section: Introductionmentioning
confidence: 99%